Crispr Therapeutics AG (CRSP) - Stock & Dividends

CRISPR Therapeutics AG, a pioneering gene editing company traded on the NASDAQ under the symbol CRSP, is dedicated to developing innovative gene-based therapies for severe diseases.

The company's core technology, CRISPR/Cas9, enables precise modifications to genomic DNA, offering a potential breakthrough in medical treatment. Their therapeutic pipeline covers a wide spectrum of conditions, including hemoglobin disorders, cancer, tissue regeneration, and rare ailments.

Leading their portfolio is CTX001, a cutting-edge ex vivo CRISPR gene therapy designed to address beta-thalassemia and sickle cell disease by enhancing fetal hemoglobin levels in patients' red blood cells.

Furthermore, CRISPR Therapeutics AG is actively researching other advanced treatments like CTX110, CTX120, and CTX130, which target various diseases through gene-edited CAR-T therapies.

Additionally, the company is developing VCTX210 and VCTX211, which are gene-edited stem cell-derived products aimed at revolutionizing the treatment of type 1 diabetes.

Established in 2013 and based in Zug, Switzerland, CRISPR Therapeutics AG has formed strategic collaborations with industry leaders like Bayer Healthcare, Vertex Pharmaceuticals, and others to advance the frontiers of gene-based medicine.

For more information about their groundbreaking work, visit their website: https://www.crisprtx.com.